Key facts
- Notable investors include US National Science Foundation, Mitsui Global Investment, Civilization Ventures, Eisai Innovation, KdT Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Tacit Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Tacit Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tacit Therapeutics
Developer of RNA-targeted treatments intended to repair mutated genes. The company works on pre-existing components of human cells and creates broadly applicable and inherently non-immunogenic means for gene modification, enabling professionals to get simple cures for genetic diseases by providing a new way to address mutations that were previously considered untreatable.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2021
- Employees
- 10
- Website
- tacittx.com/
- Ownership
- Privately Held (backing)
Tacit Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tacit Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tacit Therapeutics in its N-PORT filings yet. We sweep new filings monthly.